ISRG - Intuitive Surgical, Inc.
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Sunnyvale,
United States
Type: Equity
ISRG price evolution
ISRG
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2750.1 | $3602 | $3435.4 | $2143 |
| Short term investments | $2473.1 | $2873.7 | $2363.8 | $2549.2 |
| Net receivables | $1130.2 | $962.7 | $904.2 | $925.3 |
| Inventory | $1220.6 | $1147.5 | $1005.2 | $946.6 |
| Total current assets | $7888 | $8902.9 | $8031.8 | $8450.5 |
| Long term investments | $2120 | $1044.9 | $1332.5 | $1886.4 |
| Property, plant & equipment | $3537.6 | $3077 | $2830.8 | $2580.2 |
| Goodwill & intangible assets | $985.4 | $986.5 | $1041.7 | $1064.9 |
| Total noncurrent assets | $7553.5 | $5809.8 | $5871.5 | $6176.2 |
| Total investments | $4593.1 | $3918.6 | $3696.3 | $4435.6 |
| Total assets | $15441.5 | $14712.7 | $13903.3 | $13053.2 |
| Current liabilities | ||||
| Accounts payable | $188.7 | $196.2 | $199.7 | $1296.5 |
| Deferred revenue | $446.1 | $394.8 | $405.2 | $417.8 |
| Short long term debt | ||||
| Total current liabilities | $1658.7 | $1676.4 | $1538.4 | $1759 |
| Long term debt | ||||
| Total noncurrent liabilities | $385.5 | $412.8 | $405.2 | $451.6 |
| Total debt | ||||
| Total liabilities | $2044.2 | $2089.2 | $1943.6 | $1759 |
| Shareholders' equity | ||||
| Retained earnings | $4743 | $4209.2 | $3807.7 | $3397.4 |
| Other shareholder equity | -$12.2 | -$56.5 | -$79.8 | $11294.2 |
| Total shareholder equity | $13307.6 | $12539 | $11879.1 | $11217.7 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2750.1 | $497.2 | $1290.9 | $1622.6 |
| Short term investments | $2473.1 | $2536.7 | $2913.1 | $3488.8 |
| Net receivables | $1130.2 | $942.1 | $782.7 | $645.5 |
| Inventory | $1220.6 | $893.2 | $587.1 | $601.5 |
| Total current assets | $7888 | $8576.8 | $5844.9 | $6625.9 |
| Long term investments | $2120 | $2623.6 | $4415.5 | $1757.7 |
| Property, plant & equipment | $3537.6 | $2374.2 | $1876.4 | $1577.3 |
| Goodwill & intangible assets | $985.4 | $1058.6 | $976.8 | $840.3 |
| Total noncurrent assets | $7553.5 | $6721 | $7710.1 | $4543 |
| Total investments | $4593.1 | $5160.3 | $7328.6 | $5246.5 |
| Total assets | $15441.5 | $12974 | $13555 | $11168.9 |
| Current liabilities | ||||
| Accounts payable | $188.7 | $1423.1 | $121.2 | $81.6 |
| Deferred revenue | $446.1 | $397.3 | $377.2 | $350.3 |
| Short long term debt | ||||
| Total current liabilities | $1658.7 | $1861.4 | $1149.8 | $965.2 |
| Long term debt | ||||
| Total noncurrent liabilities | $385.5 | $439.3 | $453.7 | $444.6 |
| Total debt | $79.9 | |||
| Total liabilities | $2044.2 | $1861.4 | $1603.5 | $1409.8 |
| Shareholders' equity | ||||
| Retained earnings | $4743 | $3500.1 | $4760.9 | $3261.3 |
| Other shareholder equity | -$12.2 | $11112.6 | -$24.2 | $24.9 |
| Total shareholder equity | $13307.6 | $11041.9 | $11901.1 | $9731.5 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1743.7 | $1755.9 | $1696.2 | |
| Cost of revenue | $576.5 | $584 | $583.2 | |
| Gross Profit | $1167.2 | $1171.9 | $1113 | |
| Operating activities | ||||
| Research & development | $249.4 | $244.4 | $244.9 | |
| Selling, general & administrative | $452 | $464.3 | $480.5 | |
| Total operating expenses | $701.4 | $708.7 | $725.4 | |
| Operating income | $465.8 | $463.2 | $387.6 | |
| Income from continuing operations | ||||
| EBIT | $517.9 | $494 | $416.3 | |
| Income tax expense | $102.2 | $73.2 | $61 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $415.7 | $420.8 | $355.3 | |
| Income (for common shares) | $415.7 | $420.8 | $355.3 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7124.1 | $6222.2 | $4358.4 | |
| Cost of revenue | $2394.6 | $2026.2 | $1497.2 | |
| Gross Profit | $4729.5 | $4196 | $2861.2 | |
| Operating activities | ||||
| Research & development | $998.8 | $879 | $595.1 | |
| Selling, general & administrative | $1963.9 | $1739.9 | $1216.3 | |
| Total operating expenses | $2962.7 | $2618.9 | $1811.4 | |
| Operating income | $1766.8 | $1577.1 | $1049.8 | |
| Income from continuing operations | ||||
| EBIT | $1939.6 | $1584.7 | $1200.8 | |
| Income tax expense | $141.6 | $262.4 | $140.2 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $1798 | $1322.3 | $1060.6 | |
| Income (for common shares) | $1798 | $1322.3 | $1060.6 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $606.2 | $415.7 | $420.8 | $355.3 |
| Operating activities | ||||
| Depreciation | $133.6 | $116.3 | $104.8 | $100.1 |
| Business acquisitions & disposals | -$1.8 | $0.2 | -$7.3 | |
| Stock-based compensation | $150.4 | $156.1 | $146.5 | $139.8 |
| Total cash flows from operations | $228.3 | $548.4 | $665.7 | $371.4 |
| Investing activities | ||||
| Capital expenditures | -$435.5 | -$256.3 | -$178.3 | -$194.1 |
| Investments | -$606.9 | -$190.5 | $743.2 | $767.2 |
| Total cash flows from investing | -$1044.2 | -$446.6 | $557.6 | $573.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$22.2 | $77.4 | $74.6 | -$249.8 |
| Net borrowings | ||||
| Total cash flows from financing | -$31.5 | $61.8 | $63.3 | -$381.2 |
| Effect of exchange rate | -$5.4 | $1.7 | $5.2 | $1.8 |
| Change in cash and equivalents | -$852.8 | $165.3 | $1291.8 | $565.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1798 | $1322.3 | $1704.6 | $1060.6 |
| Operating activities | ||||
| Depreciation | $454.8 | $392.4 | $332.2 | $293.3 |
| Business acquisitions & disposals | -$8.9 | -$12.8 | -$8.7 | -$37.7 |
| Stock-based compensation | $592.8 | $513.2 | $449.2 | $395.4 |
| Total cash flows from operations | $1813.8 | $1490.8 | $2089.4 | $1484.8 |
| Investing activities | ||||
| Capital expenditures | -$1064.2 | -$532.4 | -$353.5 | -$341.5 |
| Investments | $713 | $1916 | -$2099.3 | -$561.4 |
| Total cash flows from investing | -$360.1 | $1370.8 | -$2461.5 | -$940.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$120 | -$2373.6 | $276.5 | $174.5 |
| Net borrowings | ||||
| Total cash flows from financing | -$287.6 | -$2572.3 | $43 | -$85.7 |
| Effect of exchange rate | $3.3 | $5.4 | -$3.4 | -$2.6 |
| Change in cash and equivalents | $1169.4 | $294.7 | -$332.5 | $455.9 |
News
Fundamentals
| Market cap | $131.28B |
|---|---|
| Enterprise value | $128.53B |
| Shares outstanding | 352.30M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 9.86 |
| Book/Share | 37.81 |
| Cash/Share | 7.81 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.15 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.76 |
| Quick ratio | 4.02 |